214 related articles for article (PubMed ID: 11089718)
1. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels.
Hoffman RM; Clanon DL; Littenberg B; Frank JJ; Peirce JC
J Gen Intern Med; 2000 Oct; 15(10):739-48. PubMed ID: 11089718
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer.
Chakraborty L; Ahmed AN; Paul BK; Haque A; Ara A; Nabi S; Nessa M
Mymensingh Med J; 2012 Jan; 21(1):98-102. PubMed ID: 22314462
[TBL] [Abstract][Full Text] [Related]
3. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
[TBL] [Abstract][Full Text] [Related]
4. The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories.
Erol B; Gulpinar MT; Bozdogan G; Ozkanli S; Onem K; Mungan G; Bektas S; Tokgoz H; Akduman B; Mungan A
Kaohsiung J Med Sci; 2014 Nov; 30(11):545-50. PubMed ID: 25458043
[TBL] [Abstract][Full Text] [Related]
5. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
6. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.
Roddam AW; Duffy MJ; Hamdy FC; Ward AM; Patnick J; Price CP; Rimmer J; Sturgeon C; White P; Allen NE;
Eur Urol; 2005 Sep; 48(3):386-99; discussion 398-9. PubMed ID: 15982797
[TBL] [Abstract][Full Text] [Related]
7. Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis.
Huang Y; Li ZZ; Huang YL; Song HJ; Wang YJ
Medicine (Baltimore); 2018 Mar; 97(13):e0249. PubMed ID: 29595681
[TBL] [Abstract][Full Text] [Related]
8. Using multiple cutpoints for the free-to-total prostate specific antigen ratio improves the accuracy of prostate cancer detection.
Hoffman RM; Clanon DL; Chavez M; Peirce JC
Prostate; 2002 Jul; 52(2):150-8. PubMed ID: 12111706
[TBL] [Abstract][Full Text] [Related]
9. The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml.
Wu CT; Chuang CK; Chou CC; Chu SH; Chen HW; Chen CS; Chiang YJ; Liao SK
Chang Gung Med J; 2000 Mar; 23(3):142-8. PubMed ID: 15641217
[TBL] [Abstract][Full Text] [Related]
10. Determination of the relative probability for prostate cancer to avoid unnecessary biopsy.
Okamura K; Takaba H; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Apr; 12(4):346-52. PubMed ID: 15948720
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
12. [Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations].
Kawai M; Okajima K; Kobayashi K; Moriyama M
Hinyokika Kiyo; 2006 Feb; 52(2):113-7. PubMed ID: 16541764
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases.
Kang SH; Bae JH; Park HS; Yoon DK; Moon DG; Kim JJ; Cheon J
Int J Urol; 2006 Jul; 13(7):910-4. PubMed ID: 16882054
[TBL] [Abstract][Full Text] [Related]
14. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
15. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
[TBL] [Abstract][Full Text] [Related]
16. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
18. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
[TBL] [Abstract][Full Text] [Related]
19. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer.
Haroun AA; Hadidy AS; Awwad ZM; Nimri CF; Mahafza WS; Tarawneh ES
Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):291-7. PubMed ID: 21422628
[TBL] [Abstract][Full Text] [Related]
20. Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist.
Hofer C; Sauerstein P; Wolter C; Scholz M; Hartung R; Breul J
Urol Int; 2000; 64(1):18-23. PubMed ID: 10782027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
